Entering text into the input field will update the search result below

Cybin to acquire DMT clinical study from Entheon Biomedical

Jun. 07, 2022 8:26 AM ETCybin Inc. (CYBN) StockENTBFBy: Dulan Lokuwithana, SA News Editor

Gratitude Concept With Heart Symbol

Eoneren/E+ via Getty Images

  • Cybin (NYSE:CYBN) added ~8% in the pre-market Tuesday after the psychedelics-focused biopharma announced that its subsidiary Cybin IRL Limited agreed to acquire a Phase 1 N,N-dimethyltryptamine (“DMT”) study from Canadian biotech Entheon Biomedical Corp. (OTCQB:ENTBF).
  • The acquisition

Recommended For You

More Trending News

About CYBN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CYBN--
Cybin Inc.